Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial
stage biotechnology company that aims to translate the genetics of
the adaptive immune system into clinical products to diagnose and
treat disease, today announced that immunoSEQ® T-MAP™ COVID was
used in the Nature study to measure the T-cell immune response
elicited by the Johnson & Johnson COVID-19 vaccine in the
context of multiple variants of SARS-CoV-2, including B 1.351 and
B.1.1.7. The study provides further evidence that the T-cell
response may contribute to protection from COVID-19. Adaptive’s
Technology was used to quantify T-cell expansion across all regions
of the virus, demonstrating that the T-cell response is broad and
unaltered by mutations that render vaccine-generated antibodies
less effective. The study was conducted by Beth Israel Deaconess
Medical Center (BIDMC) in Boston, MA.
“Our data generated in collaboration with Adaptive
Biotechnologies highlight the potent and
broad T-cell immune responses induced by the Ad26.COV2.S
COVID-19 vaccine in humans, including against virus variants,” said
Dan Barouch, M.D., Ph.D., Director of the Center for Virology and
Vaccine Research at BIDMC. “Using TCRbeta sequencing together
with traditional functional T-cell assays, we are able to
understand and quantify T-cell expansion to different parts of the
spike protein with precision and scale that wouldn’t have been
possible even a few years ago.”
In the multinational phase 3 ENSEMBLE trial, participants given
Johnson & Johnson’s vaccine experienced similar efficacy
against the B.1.351 variant. To understand the mechanism of
protection, the COV1001 phase 1/2 trial analyzed blood samples from
20 vaccinated individuals to measure antibody immune response
(humoral immune response) and T-cell response (cellular immune
response) against the original SARS-CoV-2 strain WA1/2020 as well
as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants.
Post-vaccination, results showed that the levels of neutralizing
antibodies were diminished against the variants, but that the
T-cell immune response was preserved, suggesting T cells may
provide protection against these emerging strains. Results indicate
T-cells may be an important correlate of protection and should be
considered as an endpoint for vaccine clinical trials.
“These findings support a growing body of evidence that
measuring T-cell response is critical to demonstrate immunity and
guide development of COVID-19 vaccines, particularly in the growing
presence of new variants,” said Harlan Robins, Ph.D., co-founder
and chief scientific officer, Adaptive Biotechnologies. “Until
recently it has been challenging to incorporate measurement of
T-cell response into vaccine clinical trials, but now immunoSEQ
T-MAP COVID provides the ability to do this at scale and with
precision using blood samples, and this technology can be applied
to many different diseases.”
immunoSEQ T-MAP COVID combines the sequencing and mapping
capabilities of Adaptive’s immune medicine platform to show how T
cells respond to different parts of the virus, including the
various parts of the spike protein. Mapping exactly how the
variants impact different parts of the virus can indicate if the
immune response is likely to be affected.
About the T cellT cells are the adaptive immune
system’s first responders to detect any virus. They quickly
multiply and circulate in the blood to attack the virus, often
before symptoms appear. Among many other jobs, T cells also recruit
B cells to produce antibodies after about a week or two to
potentially provide immunity against future infection. T cells
contain a treasure trove of information that could provide one
consistent and trackable measure of the immune response to COVID-19
from initial exposure through viral clearance.
T cells can “remember” prior infections and kill pathogens if
they reappear. Research shows that antibodies to SARS-CoV-2 decline
over time. T cells hold important clues to immunity and correlates
of protection and need to be studied to assess how long patients
remain resistant to reinfection. Given T cells circulate freely in
the blood, they are an easy and thus a desirable target for
assessing SARS-CoV-2 exposure and potentially immunity.
About immunoSEQ T-MAP COVID The immunoSEQ®
T-MAP™ COVID offering provides tools for researchers to study the
COVID-19 T-cell immune response, including detecting past
SARS-CoV-2-specific immune response in research samples and the
ability to track responses longitudinally. immunoSEQ T-MAP COVID
can detect past SARS-CoV-2-specific T-cell immune response with
a simple positive/negative result in research samples and
track responses longitudinally. Users have access to
Adaptive’s SARS-CoV-2-specific T-cell receptor database (TCR)
database to determine if samples show SARS-CoV-2-specific TCRs
and the antigens to which these TCR responded. The tool can be used
to study the T-cell immune response for vaccine research across
COVID-19 variants., mapping across
>160K SARS-CoV-2-specific antigen-TCR sequence-level data.
immunoSEQ T-MAP COVID can dive into sequence, patient or
population-level data, as well as determine TCR clones shared
between cohorts and those that are public vs private clones.
immunoSEQ T-MAP COVID is For Research Use Only. Not for use in
diagnostic procedures.
About
Adaptive Biotechnologies Adaptive
Biotechnologies is a commercial-stage biotechnology company
focused on harnessing the inherent biology of the adaptive immune
system to transform the diagnosis and treatment of disease. We
believe the adaptive immune system is nature’s most finely tuned
diagnostic and therapeutic for most diseases, but the inability to
decode it has prevented the medical community from fully leveraging
its capabilities. Our proprietary immune medicine platform reveals
and translates the massive genetics of the adaptive immune system
with scale, precision and speed to develop products in life
sciences research, clinical diagnostics and drug discovery. We have
three commercial products and a robust clinical pipeline to
diagnose, monitor and enable the treatment of diseases such as
cancer, autoimmune conditions and infectious diseases. Our goal is
to develop and commercialize immune-driven clinical products
tailored to each individual patient. For more information, please
visit adaptivebiotech.com and follow us
on www.twitter.com/adaptivebiotech.
Forward Looking Statements This press release
contains forward-looking statements that are based on management’s
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations, including forward-looking
statements contained in this press release or elsewhere related to
the immune response to COVID-19, vaccine development, and the
accuracy and functionality of immunoSEQ T-MAP COVID.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with
the Securities and Exchange Commission from time to time.
We caution you that forward-looking statements are based on a
combination of facts and factors currently known by us and our
projections of the future, about which we cannot be certain. As a
result, the forward-looking statements may not prove to be
accurate. The forward-looking statements in this press release
represent our views as of the date hereof. We undertake no
obligation to update any forward-looking statements for any reason,
except as required by law.
ADAPTIVE MEDIA: Beth
Keshishian917-912-7195media@adaptivebiotech.com
ADAPTIVE INVESTORS:Karina
Calzadilla201-396-1687Carrie Mendivil, Gilmartin
Groupinvestors@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Sep 2023 to Sep 2024